Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates

Rigel Pharmaceuticals (RIGL) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of$ 0.37. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 83.78%. A quarter ago, it was expected that this drug developer would post a loss of$ 0.30 per share when it actually produced a loss of $0.50, delivering a surprise of -66.67%. Over the last four quarters, the comp ...